What Can You Expect at the Premier RNA Drug Discovery Summit in 2026?
As RNA-targeting small molecules move toward therapeutic validation, the field is reaching a point where target selection, selectivity and translational confidence are critical. The 9th RNA-Targeted Drug Discovery & Development Summit will showcase key advances across splice modulation, RNA degradation, direct binding, translation inhibition, epitranscriptomics and induced-proximity strategies.
The agenda tracks progress from RNA modulation and AI-driven structure prediction through screening, design and validation. With case studies across oncology, rare neurological disease and neurodegeneration, attendees will gain a clear view of which approaches are ready to move into developable, clinically relevant programs.
The summit also brings together experts across RNA biology, chemistry and drug development. It offers a space to connect, validate targets and strengthen the evidence needed to move RNA-targeted small molecules toward real therapeutic impact.
What Makes This Event Unique?
The only forum dedicated exclusively to RNA-Targeted Small Molecules
Capturing innovation across RNA splice modulators, covalent binders, proximity inducing drugs, and direct RNA binders
Intimate collaboration & networking among 80+ industry-based medicinal chemists, RNA experts, structural biologists & more
Unmissable Event Highlights
AI-Driven RNA Targeting
Prioritize functional RNA targets with practical insights into how scalable screening and AI-enabled structure prediction are being used to move beyond ligandability alone to select RNA targets with stronger biological relevance, tractability and therapeutic potential with AstraZeneca, Atomic AI and RevoNA Bio
Expanding RNA Chemical Space
Expand productive RNA-focused chemical space beyond familiar chemotypes and crowded patent landscapes by exploring fragment discovery, RNA recognition principles, HARIBOSS++, SHAMAN modelling and structure-informed design with University of Colorado Boulder, University of Toronto and Sanofi
Advancing RNA Therapies to the Clinic
Translate sequence-directed RNA modulation into clinical progress by hearing how mechanistic insight into splice-site recognition is being used to expand targetable RNA sequences, strengthening candidate progression, and generating early clinical confidence across oncology and rare neurological disease with PTC Therapeutics, ReviR Therapeutics and Remix Therapeutics.
Driving RNA Therapeutic Outcomes
Transform direct RNA binding into functional therapeutic outcomes by uncovering how RNA binders, covalent translation inhibitors and induce-proximity approaches are being used to drive translation knockdown and restore disease-relevant RNA function with UNC Chapel Hill, Wayfinder Biosciences, Arrakis Therapeutics, Syrna Therapeutics and Ribometrix.
Future of RNA Small Molecules
Explore the future of RNA-targeted small molecules by examining how condensate modulation and epitranscriptomics could expand druggable target space and support future applicability in common indications with Dewpoint Therapeutics, EPICS Therapeutics, Sanofi, Pfizer and Ribonaut Therapeutics.
Explore the Full Event Guide
- Connect With 80+ RNA-Targeted Small Molecule Experts Including PTC Therapeutics, Remix Therapeutics, Arrakis Therapeutics, AstraZeneca, Sanofi and More
- Hear From 18+ Expert-Led Case Studies Spanning RNA Target Discovery, Chemistry, Optimization, Validation and Translation
- Join 3 Interactive Workshops on Functional RNA Target Selection, RNA Structure Probing and RNA-Focused Chemical Space
- Access New Data Across Splice Modulation, Direct RNA Binding, Fragment Discovery, Covalent Translation Inhibition and Kinetic Characterization
- Attend Dedicated Discussions Tackling How to Select the Right Screening Strategy, Build RNA-Focused Libraries, Measure Selectivity, and More
- Be Part of the Industry’s Only Dedicated Forum for RNA-Targeted Small Molecules
Attending Companies Include
Explore the Agenda
Hear the latest industry advances in RNA target selection, structure-guided design, selective modulation and translational strategies across the full RNA-targeted small molecule pipeline and during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Connect with RNA-targeted small molecule leaders across discovery, preclinical and clinical development during our dedicated networking sessions to exchange insights, build collaborations and strengthen decisions from target selection to therapeutic impact.